

Primary Care HEDIS Measures

Key	Population Health Measures	HEDIS 2014?	CMS Star?	Specification File
1 BSC	Breast Cancer Screening	Y	Y	Breast_Cancer_Screening.pdf
2 CCS	Cervical Cancer Screening	Y		Cervical_Cancer_Screen.pdf
3 CHL	Chlamydia Screening	Y		Chlamydia_Screen.pdf
	Age 16 - 20			
	Age 21 - 24			
	Overall			
4 COL	Colorectal Cancer Screening	Y	Y	Colorectal_Cancer_Screen.pdf
5 CIS	Childhood Immunization Status	Y		
	Chicken Pox Vaccine			Chicken_Pox_Vaccine.pdf
	Diphtheria Tetanus Pertussis Vaccine			Diphtheria-Tetanus-Pertussis_Vaccine.pdf
	Hepatitis B Vaccine			Hepatitis_B_Vaccine.pdf
	H Influenza Type B Vaccine			H_Influenza_TypeB_Vaccine.pdf
	Measles Mumps Rubella Vaccine			Measles-Mumps-Rubella_Vaccine.pdf
	Pneumococcal Conjugate Vaccine			Pneumococcal_Conjugate_Vaccine.pdf
	Polio Vaccine			Polio_Vaccine.pdf
6 LSC	Lead Screening in Children	Y		
7 GSO	Glaucoma Screening in Older Adults	Y	Y	Proposed to be removed for 2015
	Well-Child Visits			
8 W15	Well-Child Visits in the First 15 Months of Life	Y		Well-Child Visits in the First 15 Months of Life.pdf
9 W34	Well-Child Visits in the 3 - 6 Years of Life	Y		Well-Child Visits in the Third Fourth Fifth.pdf
10 AWC	Adolescent Well Care Visits	Y		Adolescent Well-Care Visits.pdf
	Managing Chronic Conditions			
	<i>Comprehensive Diabetes Care</i>			
11 CDC-H1C	Hemoglobin A1c (HbA1c) Testing	Y		Diabetes_HbA1c_Test.pdf
	HbA1C Good Control (<7%)	Y	Y	
	HbA1C Adequate Control (<8%)	Y	Y	Diabetes-HbA1c_LessThan_8percent.pdf
	HbA1C Poor Control (>9%)	Y	Y	
12 CDC-EE	Eye Exam (Retinal)	Y	Y	Diabetes-Eye_Exam.pdf
13 CDC-LDL	Cholesterol Management for Patient with Diabetes			
	LDL-C Testing	Y	Y	Diabetes-Lipid_Test.pdf
	LDL-C Control (<100 mg/dl)	Y	Y	Diabetes-LDL-C_LessThan_100mg.pdf
14 CDC-MAN	Medical Attention for Nephropathy	Y	Y	Diabetes-Microalbumin_Test.pdf
15 CDC-BPC	Blood Pressure Control	Y		
	<140/90 mmHg			
	<140/80 mmHg			
	<i>Additional Chronic Care Measure</i>			
16 AMR	Asthma Medication Ratio	Y		Asthma_Medication_Management.pdf
	Age 5 - 11			
	Age 12 - 18			
	Age 19 - 50			
	Age 51 - 64			
	Overall			
17 CMC	Cholesterol Management for Patient with Cardiovascular Conditions	Y	Y	
	LDL-C Testing	Y	Y	CAD_Event-Cholesterol_Test.pdf
	LDL-C Control (<100 mg/dl)	Y	Y	CAD-LDL-C_Less_than_100mg.pdf
18 MPM	Annual Monitoring for Persistent Medication	Y	Y	
	ACE Inhibitors or ARBs			AnnualMonitoring-ACE_ARB_Drugs.pdf
	Digoxin			AnnualMonitoring-Digoxin.pdf
	Diuretics			AnnualMonitoring-Diuretics.pdf
	Anticonvulsants Carbamazepine			AnnualMonitoring-Anticonvulsant-Carbamazepine.pdf
	Anticonvulsants Phenobarbital			AnnualMonitoring-Anticonvulsant-Phenobarbital.pdf
	Anticonvulsants Phenytoin			AnnualMonitoring-Anticonvulsant-Phenytoin.pdf
	Anticonvulsants Valproic Acid			AnnualMonitoring-Anticonvulsant-Valproic_Acid.pdf
	Overall			

Other Measures

19 CWP	Appropriate Testing for Children with Pharyngitis	Y	Pharyngitis_Treatment-Children.pdf
20 URI	Appropriate Treatment for Children with Upper Respiratory Infection	Y	URI_Treatment_Without_Antibiotics-Children.pdf
21 AAB	Avoidance of Antibiotics Treatment in Adults with Acute Bronchitis	Y	Acute_Bronchitis_Tx_Without_Antibiotics.pdf
LBP	Use of Imaging Studies for Low Back Pain	Y	Low_Back_Pain_Imaging_Studies.pdf

Age group	USA 100% (percent of the population)
Population	308 745 538
0-4	20 201 362 (6.5%)
9-May	20 348 657 (6.6%)
14-Oct	20 677 194 (6.7%)
15-19	22 040 343 (7.1%)
20-24	21 585 999 (7.0%)
25-29	21 101 849 (6.8%)
30-34	19 962 099 (6.5%)
35-39	20 179 642 (6.5%)
40-44	20 890 964 (6.8%)
45-49	22 708 591 (7.4%)
50-54	22 298 125 (7.2%)
55-59	19 664 805 (6.4%)
60-64	16 817 924 (5.4%)
65-69	12 435 263 (4.0%)
70-74	9 278 166 (3.0%)
75-79	7 317 795 (2.4%)
80-84	5 743 327 (1.9%)
85+	5 493 433 (1.8%)

Age	% population	
0-4	6.5	65
5-9	6.6	131
10-14	6.7	198
15-19	7.1	269
20-24	7	339
25-29	6.8	407
30-34	6.5	472
35-39	6.5	537
40-44	6.8	605
45-49	7.4	679
50-54	7.2	751
55-59	6.4	815
60-64	5.4	869
65-69	4	909
70-74	3	939
75-79	2.4	963
80-84	1.9	982
85+	1.8	1000

0.2588996764

% population



